Bevacizumab Treatment For Type 1 ROP
a study on Retinopathy of Prematurity Premature Birth
Summary
- Eligibility
- for people ages up to 6 months (full criteria)
- Location
- at Irvine, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Official Title
Bevacizumab Treatment For Type 1 Retinopathy of Prematurity
Details
Infants with type 1 ROP and no prior treatment for ROP will be randomly assigned (1:1) to treatment with either intravitreous bevacizumab 0.063 mg or either intravitreous bevacizumab 0.25 mg. Study exams will be at 1 day, 4 days (if no improvement on day 1), 1, 2, 3, and 4 weeks, and at 2 and 4-months post-treatment (and re-treatment when indicated). Additional study exams will occur at adjusted age 6 and 12 months. Non-study examinations will be at clinician discretion and are likely to occur more often. The primary outcome will be treatment success within each dose group, defined as improvement by the day 4 exam and no recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4 weeks of injection. Important secondary outcomes include safety and efficacy. refractive outcomes, and the extent of retinal vascularization at 2 and 4 months post-injection between the two dose groups.
Keywords
Retinopathy of Prematurity, Retinal Diseases, Premature Birth, Bevacizumab, Bevacizumab- 0.063 mg, Bevacizumab- 0.25 mg
Eligibility
You can join if…
Open to people ages up to 6 months
The study participant must have at least one eye meeting all of the inclusion criteria in order to be eligible to participate:
- Birth weight < 1251 grams
- Newly diagnosed (within 2 days) type 1 ROP in zone I in one or both eyes
You CAN'T join if...
Participants meeting any of the following exclusion criteria will be excluded from study participation.
- Previous treatment for ROP
- Stage 4 or 5 ROP in either eye
- Treatment could not be done within 2 days of diagnosis of type 1 ROP
- Investigator unwilling to randomize or parent unwilling to accept randomized assignment to either treatment
- Transfer to another hospital anticipated within the next 4 weeks where exams by study-certified examiners are not available. If hospital discharge is anticipated within the next 4 weeks, parents unable or unwilling to return to the PEDIG site for outpatient follow-up visits.
- Active ocular infection or purulent nasolacrimal duct obstruction in either eye
One eye will be excluded, and other eye may be eligible, if either of the following are present:
- Visually significant ocular anomaly (e.g., cataract, coloboma)
- Opacity that precludes an adequate view of the retina
Locations
- Univ of California, Irvine- Gavin Herbert Eye Institute
accepting new patients
Irvine California 92697 United States - Jules Stein Eye Institute at the University of California, Los Angeles
accepting new patients
Los Angeles California 90095 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Jaeb Center for Health Research
- Links
- PEDIG Public Website
- ID
- NCT04634578
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 80 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.